Recently, the momentum of AI utilization in the pharmaceutical development world has accelerated rapidly, which is quite interesting. News has emerged that Takeda Pharmaceutical signed a multi-year contract exceeding $1.7 billion with a company called Iambic. They plan to use AI to design small-molecule drugs targeting cancer and gastrointestinal diseases. In addition to an upfront payment, Iambic's structure includes milestone rewards based on progress in development and commercialization, as well as sales royalties. Last year, Takeda signed a similar contract with Nabla Bio for protein-based drugs, indicating that these companies are seriously shifting toward AI-driven drug discovery. The model provided by Iambic, called NeuralPLexer, is said to predict how drug molecules will bind to proteins. CEO Tom Miller commented, "If you don't understand the shape of the protein, it's like sculpting in the dark." In fact, traditional drug discovery can take about six years until compounds reach clinical trials, but Iambic claims they can reduce this to less than two years. Takeda's Chief Scientific Officer, Christopher Arendt, emphasized that not only speed but also the quality of molecules is equally important. Experts predict that as this trend spreads throughout the entire pharmaceutical industry, development times could be halved in the coming years. Technologies from companies like Iambic might become game changers in drug development.